Navigation Links
Scientists report major advance in human antibody therapy against deadly Hendra virus
Date:10/19/2011

Bethesda, MDA team of Federal and university scientists reports a breakthrough in the development of an effective therapy against a deadly virus, Hendra virus. The results of their study, "A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge," will appear in Science Translational Medicine online. The full study will be available following the release of the embargo at 2 p.m. Oct. 19, 2011.

The collaborative research team members are from the Uniformed Services University of the Health Sciences (USU), the University of Texas Medical Branch (UTMB) and Galveston National Laboratory (GNL), the National Institutes of Health (NIH's) National Institute of Allergy and Infectious Diseases (NIAID), Rocky Mountain Laboratories (RML), the National Emerging Infectious Diseases Laboratories Institute (NEIDL) at Boston University School of Medicine, and the National Cancer Institute (NCI), NIH. The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. manages the patent and played a central role in the transfer of the antibody and cell line to Queensland Health in Australia in 2010.

Hendra virus and the closely related Nipah virus are found in Pteropid fruit bats (flying foxes) and are emerging viruses capable of causing severe illness and death in a variety of domestic animals and humans.

In experiments carried out in African green monkeys at the RML in Hamilton, Montana, where there is a high-level safety and security facility for working with live Hendra virus, the team of researchers, under the direction of Heinz Feldmann, M.D., Ph.D., chief of the RML, Laboratory of Virology, demonstrated that giving an anti-virus human monoclonal antibody therapy after exposure to Hendra virus protected the animals from disease.

"These findings are really quite promising and appear to offer a real potential treatment for Hendra virus infection in people," said Christopher C. Broder, Ph.D., Professor of Microbiology at USU and study corresponding author.

Earlier work at USU and NCI, supported by NIAID conducted under the direction of Dr. Broder and study co-author Dimiter S. Dimitrov, Ph.D., Sc.D., senior investigator at NCI, resulted in the discovery and development of a human monoclonal antibody, m102.4, in work carried out by Zhongyu Zhu, Ph.D. The m102.4 antibody attacks a critical component of Hendra virus and Nipah viruses and prevents their infection of cells. Antibodies proteins found in blood or other bodily fluids of vertebrates are used by the immune system to identify and neutralize viruses and bacteria.

According to study co-author Thomas W. Geisbert, Ph.D., professor in the Department of Microbiology and Immunology at UTMB and the GNL, "We now have good evidence that this antibody could save human lives. The success of the antibody therapy against Hendra virus disease in a nonhuman primate model is a major step forward in developing it for future therapeutic use in people."

Previous work by study coauthor Barry Rockx, Ph.D., formerly of the Laboratory of Virology at the RML and now assistant professor in the Department of Pathology at UTMB, described the Hendra virus nonhuman primate model used in this study which now demonstrates that the m102.4 antibody given as late as three days following infection by Hendra virus, could still save the animals from lethal disease. Major support for the current study came from NIAID, NIH, including grant U01-AI082121 awarded to Dr. Geisbert.

Katharine Bossart, Ph.D., a USU alumna, now an assistant professor in the Department of Microbiology, Boston University School of Medicine, led a collaborative study in Australia that provided the first evidence of the antibody's effectiveness in preventing Nipah virus mediated disease in an animal model.

"This new evidence that m102.4 is highly effective against Hendra virus in a second animal model provides crucial new data justifying further pre-clinical development of the antibody as a therapy against both Hendra and Nipah virus infection of humans."

"There are no other known or effective therapeutic options for Hendra virus infection," according to Dr. Broder. "Indeed, because of the recent emergency compassionate use of the antibody in two individuals last year in Queensland, Australia, who were exposed to Hendra virus from an ill horse, we transferred the materials needed for producing it to Queensland Health officials, at their request. This allows larger amounts of m102.4 to be prepared locally using proper manufacturing guidelines and will make the antibody available for compassionate use in Australia should it be needed in any future outbreak."

Hendra virus and Nipah virus, members of the paramyxovirus family, are highly infectious agents that emerged from flying foxes in the 1990s to cause serious disease outbreaks in humans and livestock in Australia, Malaysia, Singapore, Bangladesh and India. Recent Nipah outbreaks have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission, and greater than 75 percent case fatality rates among humans. Additionally, these properties make these viruses a concern to both human and livestock health.

The present findings indicate that m102.4 could potentially be used as a post-exposure drug, diagnostic probe or research reagent. Hendra virus has re-emerged every year in eastern Australia since 2004. In 2009, Hendra virus caused the death of several horses and one person in Australia. In 2010, a single appearance of Hendra virus infection of a horse resulted in a significant risk of exposure to two people. Because no other therapeutic measures against Hendra virus infection exist, a decision to administer the m102.4 monoclonal antibody was made by Australian health officials. Both these individuals remain healthy today.

The 2011 Hendra virus outbreak in Australia has been unprecedented. Since late June, there have been 18 separate outbreaks of Hendra virus infection of horses in Queensland and New South Wales resulting in the deaths of numerous animals. Hendra infection was also reported in a dog, but fortunately, no cases of human infection have been seen this year. The most recent appearance of Hendra virus was on Oct. 11, 2011, with health officials declaring it endemic in New South Wales in addition to Queensland.

"There are currently no licensed and approved vaccines or therapeutics for prevention and treatment of disease caused by these viruses for humans or livestock," said Dr. Broder. "This human monoclonal antibody is the first effective antiviral drug against Hendra virus and Nipah virus that has a real potential for human therapeutic applications."

The human monoclonal antibody, m102.4 is protected under issued and pending patents in many countries around the world.


'/>"/>

Contact: JoAnn Sperber
jsperber@hjf.org
240-694-2163
Henry M. Jackson Foundation for the Advancement of Military Medicine
Source:Eurekalert

Related biology news :

1. Magnifying research: Scientists team together to upgrade supercomputer
2. Scientists first to characterize barley plant-stem rust spore communication
3. Scientists discover dietary moisture window that boosts urinary tract health in cats
4. Southampton scientists herald significant breakthrough in study of chlamydia
5. Scientists move closer to predicting who will and will not fight off severe infections
6. Tagging tumors with gold: Scientists use gold nanorods to flag brain tumors
7. Uncharted territory: Scientists sequence the first carbohydrate biopolymer
8. New drug target for Alzheimers, stroke is discovered by University at Buffalo scientists
9. Scientists discover 3 new gene faults which could increase melanoma risk by 30 percent
10. Scientists identify microbes responsible for consuming natural gas in Deepwater Horizon spill
11. University of Texas marine scientists awarded $5.6 million for study of critical Arctic environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... USA (PRWEB) , ... April 26, 2017 , ... ... on FDA’s GMP expectations for phase I clinical trials comes to Tampa, San ... various biotechnology and pharma professionals representing FDA regulated organizations such as Pfizer Inc., ...
(Date:4/26/2017)... 26, 2017  Genisphere LLC, provider of the ... a collaborative and sponsored research agreement with the ... . The overall goal of the partnership is ... 3DNA designs and formulations after in vivo ... the vasculature as well as inflammatory responses, demonstrating ...
(Date:4/25/2017)... ... 2017 , ... Dr. Robert G. Schwartz, the principal of ... that acclaimed physiatrist Matthew Terzella, MD, has joined the practice as a partner, ... completed his residency in Physical Medicine and Rehabilitation at UMDNJ-Robert Wood Johnson and ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... 10 categories with over 30 nominees and well as the first-year award for ... award and the event was hosted by CompanyWeek and Manufacturers Edge, among other ...
Breaking Biology Technology: